To capture the menace of mythological monsters, the rambunctiousness of Santa’s reindeer, or the whimsy of Wallace and Gromit, animators have sequenced still images of objects that move, just a tiny bit, from image to image. Something like this animation technique, which is called claymation or stop-motion photography, has now been used to detail the shape-shifting ways of a large DNA-binding protein complex, transcription factor IID (TFIID). TRIID isn’t made of clay, but it is bendy, even floppy, and it has, if anything, more moving parts than the average dragon.

Crisp and clear TFIID snapshots were recently captured by University of California (UC), Berkeley, scientists using cryo-electron microscopy (cryo-EM). These snapshots, the scientists said, include images of human TFIID alone and in various stages of promoter binding. Combining their cryo-EM work with chemical crosslinking mass spectrometry data and biochemical reconstitution, the scientists determined the complete structure of TFIID and the functional conformational landscape of the complex.

These findings are valuable because TFIID is critical to transcribing genes into RNA that will later be used as blueprints to make proteins. Besides improving our understanding of how TFIID translates (and sometimes fails to translate) the operating instructions of our genome, the findings could help drug designers create drugs that interfere with the molecule’s structural changes. Such drugs could tweak the expression of disease-causing genes.

Details of the UC Berkeley team’s work appeared in the journal Science, in an article titled, “Structure of human TFIID and mechanism of TBP loading onto promoter DNA.” The article presents five distinct structural states of the TFIID complex. “Our studies,” the article’s authors wrote, “lead to a mechanistic model of TATA-box binding protein (TBP) loading onto the promoter by TFIID and TFIIA, and provide insights into how TFIID may engage chromatin, respond to transcriptional activators, and serve as a scaffold for preinitiation complex (PIC) assembly.”

“These structures give you the potential for rationally designing small molecules that will disturb the normal function, because now we don’t have just a single structure, we have many structures, which is even more powerful because we can target the motion that we are seeing right now,” said Eva Nogales, Ph.D., senior author of the study and a UC Berkeley professor of molecular and cell biology and a faculty scientist at Lawrence Berkeley National Laboratory.

“Where you stick that drug and how you make that drug operate is highly dependent on the transient nature of these structures, and that is something we have come to realize only very recently,” said Robert Tjian, Ph.D., a UC Berkeley professor of molecular and cell biology who discovered TFIID and has worked on the molecule for much of his career, though he was not a co-author of the new paper. “Because these molecules are moving around and their structures are so complicated, conventional drug discovery would never reveal what is going on. Dr. Nogales’ structures are going to change that. This has the potential to open up the universe of druggable targets.”

TFIID is an agglomeration of more than a dozen distinct proteins that homes in on a promoter—a region of DNA that controls the transcription of a nearby gene—and tests the sequence to make sure it has landed at the right spot. Once this is confirmed, it opens up to recruit dozens of other proteins that then start ratcheting along the gene, using the DNA sequence as a template to create a complementary sequence of RNA, called messenger RNA. This then wends its way out of the nucleus into the body of the cell, where it is translated by other molecular machines into protein.

“TFIID is probably the hardest structure anybody has tried to solve because it is massive and it is highly flexible,” said Dr. Tjian. “The only way you can see these very flexible structures is by cryo-EM, and Dr. Nogales can now freeze all these different flexible states and describe the movement.”

Cryo-EM involves freezing a drop containing millions of copies of a molecule, in every imaginable orientation, and using an electron microscope to determine the structure by combining images to define the 3D shape. Because TFIID has many moving parts as it binds to DNA and gets ready to transcribe a gene, averaging all the frozen positions produces a blurred image.

Dr. Nogales compares previous efforts at imaging TFIID, including her own attempts going back nearly 20 years, to taking a photograph of a soccer team on the field and averaging the motions of all the players. The result is a generic human torso with blurry head and limbs.

Now, thanks to more than two years of intensive work by Patel and Louder, it’s possible to capture higher resolution images that are akin to distinguishing a striker’s leg kick from a goalie’s hand block and a fullback’s header.

“Imagine you have an image of the 22 soccer players on the field, and you were to combine them into a single unit that you would call the ‘generic soccer player,'” she said. “It will look like a blurry picture—you could barely see that it’s a humanoid form and that there is some kind of motion, but you wouldn’t realize that a difference exists between the players.”

The improved pictures are a result of better detectors developed originally by colleagues at Berkeley Lab, and steadily improving computer algorithms to analyze the huge amounts of data collected by the detectors. This helped Dr. Nogales and her team to define five distinct structures of the TFIID molecule.

“They span the whole binding sequence: before binding to the DNA, initial binding to the promoter, subsequent binding after it double checks that this is the right place, and the final state,” Dr. Nogales said.

She and her colleagues continue to push the limits of cryo-EM, hoping to determine the 3D structure of TFIID after other transcription proteins land on it to complete the transcription process.

Previous articleLeo Pharma, PellePharm Launch $760M+ Rare Skin Disease Alliance
Next articleMerck KGaA, Palantir Create Cancer Collab to Develop New Research Platform